-
ASH 2024 | Dr. Yang Liang: New Insights and Future Perspectives on Clonal Hematopoiesis
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis…
-
ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions…
-
SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment
In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases,…
-
SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients
The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on…
-
SABCS 2024 | Dr. Biyun Wang: Pharmacokinetics and Preliminary Efficacy of GQ1001 Combined with Pyrotinib in HER2+ MBC Patients Previously Treated
The treatment of HER2-positive breast cancer remains a focal point in clinical research. At the 2024 San Antonio Breast Cancer Symposium (SABCS), a phase 1b study led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center presented promising results (Abstract No. P5-05-02). This study explored the pharmacokinetics and preliminary efficacy of a novel HER2…
-
Dr. Nanlin Li: Efficacy and Safety of Envafolimab Combined with Pyrotinib and Nab-Paclitaxel in Neoadjuvant Therapy for HER2-Positive Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium (SABCS), one of the world’s most prestigious events in breast cancer research, Chinese scholars once again demonstrated their exceptional expertise and innovative spirit in the field of breast cancer treatment. A groundbreaking study led by Dr. Nanlin Li and his team from Xijing Hospital of the Air…
-
Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk
From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many…
-
Dr. Tao Sun: Efficacy and Safety of the Triple Combination of Penpulimab, Anlotinib, and Nab-Paclitaxel as First-Line Therapy for Advanced TNBC
Among breast cancer subtypes, triple-negative breast cancer (TNBC) has long been a clinical challenge due to its high malignancy and poor prognosis. Traditional therapies for advanced TNBC often yield suboptimal results, but the rise of immunotherapy has brought new hope to patients.
Connecting Medical Expertise through Media